Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02596230 · ClinicalTrials.gov registry record
RE-COVERY DVT/PE: Global Study on Treatment Secondary Prevention of Acute Venous Thromboembolism
A clinical trial, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- 7,797
- Enrollment target
NCT02596230 is a clinical trial that has completed, run by Boehringer Ingelheim. The registered enrollment target is 7,797 participants.
The verdict
NCT02596230 has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- 7,797 participants
- Enrollment target
Study Summary
RE-COVERY is a large, multi-national, multi-center observational study based on new data collection. The study will enroll and characterize patients within 30 days of being diagnosed with an acute DVT and/or PE. The study has two main objectives. Objective 1 will characterize the DVT / PE patient population. All patients with a DVT and/or PE will be enrolled for cross-sectional characterization of the VTE patient population. Objective 2 will compare the safety and effectiveness of dabigatran etexilate regimens for treatment of VTE in comparison to VKA regimens. Patients treated with dabigatran etexilate or VKA will be followed up for the occurrence of outcome events for up to one year.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7,797 participants |
| Start Date | 2015-11-05 |
| Est. Completion | 2019-03-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02596230
The ClinicalTrials.gov registry entry for NCT02596230 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 7,797 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT02596230 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02596230 about?
NCT02596230 is a clinical study titled "RE-COVERY DVT/PE: Global Study on Treatment Secondary Prevention of Acute Venous Thromboembolism". RE-COVERY is a large, multi-national, multi-center observational study based on new data collection. The study will enroll and characterize patients within 30 days of being diagnosed with an acute DVT and/or PE. The study has two main objectives. Objective 1 will characterize the DVT / PE patient po...
What is the current status of trial NCT02596230?
This trial is currently completed. The enrollment target is 7,797 participants. The study started on 2015-11-05. Estimated completion is 2019-03-31.
Who is sponsoring clinical trial NCT02596230?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.